Launch Alnylam 2030 strategy
KEY STEPAlnylam formally launched its five year Alnylam 2030 strategy, setting targets for TTR leadership, nucresiran launches, revenue growth, operating margin and pipeline expansion through 2030.
Roadmap referenceAlnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutic...
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Alnylam formally launched its five year Alnylam 2030 strategy, setting targets for TTR leadership, nucresiran launches, revenue growth, operating margin and pipeline expansion through 2030.
Roadmap referenceAlnylam reported first quarter 2026 global net product revenue of $1.036 billion, marking the first time the company exceeded $1 billion of product revenue in a single quarter. Total TTR net product revenue was $910 million, driven primarily by AMVUTTRA.
Roadmap referenceAlnylam reported $1.030 billion of total TTR net product revenue in the second quarter of 2026, marking the first quarter in which the TTR franchise exceeded $1 billion of revenue. AMVUTTRA contributed $1.012 billion of the total.
Roadmap referenceMember of Scientific Advisory Board
Company leadership profile.
Independent Director
Company leadership profile.
Co-Founder, Member of the Scientific Advisory Board
Company leadership profile.
Independent Chair of the Board
Company leadership profile.
Independent Director
Company leadership profile.
CEO & Director
Company leadership profile.
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Member of the Scientific Advisory Board
Company leadership profile.
Member of Scientific Advisory Board
Company leadership profile.
Member of Scientific Advisory Board
Company leadership profile.
Member of the Scientific Advisory Board & Independent Director
Company leadership profile.
Member of Scientific Advisory Board
Company leadership profile.
Member of Scientific Advisory Board
Company leadership profile.
Member of Scientific Advisory Board
Company leadership profile.
Independent Director
Company leadership profile.
Member of the Scientific Advisory Board
Company leadership profile.
Independent Director
Company leadership profile.
Director
Company leadership profile.
1 expert evaluated Alnylam.
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy